AlphaTON’s Cyncado Therapeutics and Australia’s ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans
Globenewswire·2025-11-12 12:00
ADDRI-sponsored trial in Australia planned to enroll approximately 50 patients, led by A/Prof Steven Kao and Dr Melvin Chin; part of Cyncado’s international program for mesotheliomaDover, DE and Sydney, Australia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today announced a non-binding Letter of Intent (LOI) between Australia’s Asbestos and Dust Diseases Research ...